- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06751030
Estrategia comunitaria, de educación en el hogar y de servicios de detección para aumentar el acceso al control del cáncer de cuello uterino para las mujeres VIH positivas en Nigeria
Estrategia comunitaria, de educación en el hogar y de servicios de detección (CHESS) para aumentar el acceso al control del cáncer de cuello uterino para mujeres VIH positivas en Nigeria
The goal of this observational study is to focus on adapting and implementing a program to promote HPV and cervical cancer (CC) screening and follow-up treatment for HIV-positive women, with three specific aims:
- Adaptation: Use stakeholder deliberation to tailor the successful MoMent program for this population.
- Implementation and Assessment: Deploy the adapted MoMent program and evaluate its reach, effectiveness, adoption, and fidelity.
- Evaluation: Conduct a post-implementation process evaluation to identify barriers and facilitators to the program's maintenance and sustainability.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Despite the increased risk of cervical cancer (CC) among women living with HIV (WLWH), access to CC screening in Nigeria remains limited. While advances in prevention programs and antiretroviral therapy have reduced other AIDS-associated malignancies, CC risk in WLWH persists. This study aims to leverage Nigeria's existing HIV treatment infrastructure to integrate home-based CC (HCC) screening for WLWH.
The approach involves adapting the MoMent (MOther MENTor) peer-based HIV support program to include HCC screening and evaluating its implementation and sustainability using the Consolidated Framework for Implementation Research (CFIR) and RE-AIM frameworks. The study has three key aims:
- Adapting the MoMent program to promote home-based HPV screening and follow-up treatment through stakeholder deliberation.
- Implementing and assessing the program's reach, effectiveness, adoption, and fidelity with a sample of 1,500 WLWH.
- Conducting a post-implementation evaluation to identify barriers and enablers for program maintenance and scalability.
Stakeholder input, including perspectives from WLWH, peer counselors, clinical managers, and policymakers, will guide the program's design and execution. By integrating stakeholder insights and addressing systemic challenges, the study aims to advance CC control in Nigeria and provide a scalable model for implementing cancer control strategies for people living with HIV in low- and middle-income countries globally.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Abuja, Nigeria
- APIN Health Initiatives
-
Ibadan, Nigeria
- University of Ibadan
-
Lagos, Nigeria
- Nigeria Institute of Medical Research (NIMR
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Aim 1: The stakeholder deliberation conferences will include stakeholders from the following groups:
- State and National Policymakers
- Organizational-clinical managers
- Mentor mothers
- Women living with HIV (WLWH) Since this is a socio-behavioral component, pregnant individuals may partake. All individuals who take part in this portion of the study will be above 18 and capable of providing informed consent.
Aim 2: This study will only include WLWH aged 25-50. Pregnant individuals will not be included due to the potential for treatment of precancerous lesions. All individuals who partake in the study will be older than 18 and capable of providing informed consent.
Descripción
Inclusion Criteria:
- Patients must be able to perform vaginal self-collection as well as give informed consent
Exclusion Criteria:
- Male gender
- Age <25 or >50
- Unknown or negative HIV status
- Pregnancy
- Hysterectomy
- Inability to give informed consent Inability/refusal to perform vaginal self-collection
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Women living with HIV
During the screening process:
WLWH testing positive for HrHPV 16/18/45 via self-collection will be notified by a Mentor Mother, who, along with Nigerian clinical staff, will assist in scheduling VIA. Treatment follows the standard of care protocol. |
The MOther MENTor (MoMent) program in Nigeria pairs trained treatment-experienced Women living with HIV (WLWH), known as Mentor Mothers (MMs), with new mothers who are newly diagnosed with HIV to improve access to and retention in HIV care
Otros nombres:
A cervical cancer screening tool. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Program Reach
Periodo de tiempo: Baseline, Month 6, Month 18
|
Reach evaluated through the provision of home test kits to eligible women, returned samples, number of WLWH positive for high-risk HPV (hrHPV) treated, persistence or reoccurrence of hrHPV or cervical precancerous lesions post-treatment, and correlation of these results with CD4 and HIV viral load. |
Baseline, Month 6, Month 18
|
|
Effectiveness of the Program
Periodo de tiempo: Baseline, Month 6, Month 18
|
Effectiveness evaluated through the provision of home test kits to eligible women, returned samples, number of WLWH positive for high-risk HPV (hrHPV) treated, persistence or recurrence of hrHPV or cervical precancerous lesions post-treatment, and correlation of these results with CD4 and HIV viral load. |
Baseline, Month 6, Month 18
|
|
Adoption of the program
Periodo de tiempo: Baseline, Month 6, Month 18
|
Adoption will be measured through the proportions of MMs who complete training and WLWH who return self-collected (SC) samples |
Baseline, Month 6, Month 18
|
|
Fidelity of the program
Periodo de tiempo: Baseline, Month 6, Month 18
|
Will be measured by peer leaders' monitoring of practices, as well as measuring system barriers and added MoMent program costs per completed home screening |
Baseline, Month 6, Month 18
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Lisa Flowers, MD, MPH, Emory University
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades uterinas
- Enfermedades Genitales Femeninas
- Neoplasias Genitales Femeninas
- Enfermedades del cuello uterino
- Neoplasias Uterinas
- Neoplasias del cuello uterino
Otros números de identificación del estudio
- STUDY00004817
- U01CA275113 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Data shared:
De-identified sociodemographic data (e.g., race/ethnicity, age). Health behavior and health care utilization data from medical records. Cervical pathology results, HPV testing data, laboratory tests (e.g., CD4 and viral load), prescribed HIV medications, and adherence data.
Qualitative data from in-depth interviews and focus group discussions, coded and anonymized.
Marco de tiempo para compartir IPD
Start Date: After primary analyses have been completed and results are published (expected within 12 months of study completion).
End Date: Indefinitely, contingent on adherence to data-sharing agreements
Criterios de acceso compartido de IPD
Researchers will submit a Data Analysis Request Form, detailing their proposed analysis, purpose, and data needed.
Data access will be granted following review and approval. Approved users will sign a Data Use and Confidentiality Agreement. Anonymized data will be shared securely via a designated data repository or encrypted file transfer.
Researchers must commit to using the data for specified purposes, implementing secure data storage, and destroying or returning the data after analyses are completed.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .